Purpose. Establishing prognostic gene signature to predict clinical outcomes and guide individualized adjuvant therapy is necessary. Here, we aim to establish the prognostic efficacy of a gene signature that is closely related to tumor immune microenvironment (TIME). Methods and Results. There are 13,035 gene expression profiles from 130 tumor samples of the non-small cell lung cancer (NSCLC) in the data set GSE103584. A 5-gene signature was identified by using univariate survival analysis and Least Absolute Shrinkage and Selection Operator (LASSO) to build risk models. Then, we used the CIBERSORT method to quantify the relative levels of different immune cell types in complex gene expression mixtures. It was found that the ratio of dendrit...
Background. Lung squamous cell carcinoma (LSCC) is a frequently diagnosed cancer worldwide, and it h...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
Lung cancer remains the leading cause of cancer-related deaths worldwide. The recurrence rate ranges...
Abstract Lung Squamous Cell Carcinoma (LUSC) is an aggressive malignancy with limited therapeutic op...
BACKGROUND: Current staging methods are inadequate for predicting the outcome of treatment of non-sm...
The development of immunotherapy has greatly changed the advanced-stage non-small-cell lung cancer (...
Growing evidence indicates that immune-related biomarkers play an important role in tumor processes....
Abstract Background Lung cancer has become the most common cancer type and caused the most cancer de...
Abstract Background The high mortality of patients with non-small cell lung cancer (NSCLC) emphasize...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
Background The prognosis of patients for lung adenocarcinoma (LUAD) is known to vary widely; the 5-y...
BACKGROUND: The tumor immune microenvironment is a heterogeneous entity. Gene expression analysis al...
BackgroundDue to the relatively insidious early symptoms of lung adenocarcinoma (LUAD), most LUAD pa...
<div><p>Although several prognostic signatures have been developed in lung cancer, their application...
Abstract Background Improved methods are needed for predicting prognosis and the benefit of deliveri...
Background. Lung squamous cell carcinoma (LSCC) is a frequently diagnosed cancer worldwide, and it h...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
Lung cancer remains the leading cause of cancer-related deaths worldwide. The recurrence rate ranges...
Abstract Lung Squamous Cell Carcinoma (LUSC) is an aggressive malignancy with limited therapeutic op...
BACKGROUND: Current staging methods are inadequate for predicting the outcome of treatment of non-sm...
The development of immunotherapy has greatly changed the advanced-stage non-small-cell lung cancer (...
Growing evidence indicates that immune-related biomarkers play an important role in tumor processes....
Abstract Background Lung cancer has become the most common cancer type and caused the most cancer de...
Abstract Background The high mortality of patients with non-small cell lung cancer (NSCLC) emphasize...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
Background The prognosis of patients for lung adenocarcinoma (LUAD) is known to vary widely; the 5-y...
BACKGROUND: The tumor immune microenvironment is a heterogeneous entity. Gene expression analysis al...
BackgroundDue to the relatively insidious early symptoms of lung adenocarcinoma (LUAD), most LUAD pa...
<div><p>Although several prognostic signatures have been developed in lung cancer, their application...
Abstract Background Improved methods are needed for predicting prognosis and the benefit of deliveri...
Background. Lung squamous cell carcinoma (LSCC) is a frequently diagnosed cancer worldwide, and it h...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
Lung cancer remains the leading cause of cancer-related deaths worldwide. The recurrence rate ranges...